Reimbursement Processes for Keytruda in Israel, UK, and Australia

By Staff Writer

February 26, 2023

Introduction:

New cancer therapies, such as pembrolizumab, come with high costs, presenting a unique challenge for resource allocation decisions across nations and healthcare systems. Developed countries with national universal health insurance coverage have established different methods. Time to Reimbursement of Pembrolizumab and other oncology treatment are of utmost importance for high level of care. These methods orderly and transparently assess new technologies before adding them to their list of reimbursed services. This process, known as the “fourth hurdle”, is a stage after a country registers the technology. Here, the new technology must show value for money. It also needs to prove its effectiveness and safety before it can qualify for reimbursement from public funds. 

International Approaches:

This research utilises a comparative approach, examining the reimbursement process for pembrolizumab, a cancer treatment drug, in three different healthcare systems: The National Institute for Health and Care Excellence (NICE) in the United Kingdom (UK), the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, and the National Advisory Committee for the Basket of Health Services in Israel. Data were collected from publicly available websites and relevant literature.

Time to Reimbursement of Pembrolizumab:

The research found significant differences in time to reimbursement in these countries, with Israel approving two conditions earlier than the UK and Australia. This paper suggests that unique healthcare policies and systems in these countries could account for these differences.

Conclusion:

The study concludes by suggesting the need for a debate on how to encourage earlier access to necessary and life-saving cancer treatments in countries where the reimbursement process is longer. The most important challenge was budget limitations among many factors that are taken into account in the reimbursement process, and length of time from registration to reimbursement in the public health system of each country.

Reference url

Recent Posts

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

HPV testing HNSCC
    

HPV Testing in Head and Neck Squamous Cell Carcinoma

🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?

Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.

Look into this essential topic and see how these insights could revolutionize clinical practices.

#SyenzaNews #oncology #HealthTech #HealthcareInnovation

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.